ArticleFrontiers in pharmacology2012
On the Role of Cannabinoid CB1- and μ-Opioid Receptors in Motor Impulsivity.
Article in Frontiers in pharmacology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- Article
- Comparative effects of cannabinoid CB1 receptor agonist and antagonist on timing impulsivity induced by d-amphetamine in a differential reinforcement of low-rate response task in male rats.Psychopharmacology · 2022Article
- Preconception paternal morphine exposure leads to an impulsive phenotype in male rat progeny.Psychopharmacology · 2021Article
- Lateral habenula cannabinoid CB1 receptor involvement in drug-associated impulsive behavior.Neuropharmacology · 2021Article
- Abuse Potential of Synthetic Cannabinoids: AM-1248, CB-13, and PB-22.Biomolecules & therapeutics · 2021Article
- Where Dopaminergic and Cholinergic Systems Interact: A Gateway for Tuning Neurodegenerative Disorders.Frontiers in behavioral neuroscience · 2021Review
- Association of a Variant ofFrontiers in genetics · 2020Article
- The neurobiology of impulsivity and substance use disorders: implications for treatment.Annals of the New York Academy of Sciences · 2019Review
- Kappa opioid receptors mediate yohimbine-induced increases in impulsivity in the 5-choice serial reaction time task.Behavioural brain research · 2019Article
- Opioid modulation of cognitive impairment in depression.Progress in brain research · 2018Review
- Persistent effects of chronic Δ9-THC exposure on motor impulsivity in rats.Psychopharmacology · 2015Article
- Increased impulsivity in rats as a result of repeated cycles of alcohol intoxication and abstinence.Addiction biology · 2015Article
- Endocannabinoids and striatal function: implications for addiction-related behaviours.Behavioural pharmacology · 2015Review
- Convergent pharmacological mechanisms in impulsivity and addiction: insights from rodent models.British journal of pharmacology · 2014Review
- Beta bursts spatiotemporal profiles and their links to hemodynamic responses during movement and rest.Imaging neuroscience (Cambridge, Mass.)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies using a rat 5-choice serial reaction time task have established a critical role for dopamine D2 receptors in regulating increments in motor impulsivity induced by acute administration of the psychostimulant drugs amphetamine and nicotine. Here we investigated whether cannabinoid CB1 and/or μ-opioid receptors are involved in nicotine-induced impulsivity, given recent findings indicating that both receptor systems mediate amphetamine-induced motor impulsivity. Results showed that the cannabinoid CB1 receptor antagonist SR141716A, but not the opioid receptor antagonist naloxone, reduced nicotine-induced premature responding, indicating that nicotine-induced motor impulsivity is cannabinoid, but not opioid receptor-dependent. In contrast, SR141716A did not affect impulsivity following a challenge with the dopamine transporter inhibitor GBR 12909, a form of drug-induced impulsivity that was previously found to be dependent on μ-opioid receptor activation. Together, these data are consistent with the idea that the endogenous cannabinoid, dopamine, and opioid systems each play important, but distinct roles in regulating (drug-induced) motor impulsivity. The rather complex interplay between these neurotransmitter systems modulating impulsivity will be discussed in terms of the differential involvement of mesocortical and mesolimbic neurocircuitry.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.